SCHEMBL5363330

SCHEMBL5363330

Cc1c(O)ccc(C=C2C(=O)Nc3c(Br)cc(Br)cc32)c1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 1/20 0.43
TAB1 Q15750 1/20 0.43
MAP1LC3B Q9GZQ8 3/20 0.42
PLK4 O00444 4/20 0.41
SIRT1 Q96EB6 3/20 0.40
SIRT2 Q8IXJ6 2/20 0.40
SIRT3 Q9NTG7 2/20 0.40
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 2/20 0.39
KMT2A Q03164 2/20 0.39
XBP1 P17861 1/20 0.39
NTSR1 P30989 1/20 0.39
RAF1 P04049 4/20 0.38
LRRK2 Q5S007 3/20 0.37
ALDH2 P05091 1/20 0.36
ALDH3A1 P30838 1/20 0.36
PLK1 P53350 3/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7136300 0.83 MAP3K7 (0.45) MAP3K7TAB1MAP1LC3BPLK4SIRT1
SCHEMBL7139752 0.82 MAP3K7 (0.39) MAP3K7TAB1MAP1LC3BPLK4SIRT1
SCHEMBL5368618 0.81 ERN1 (0.46) MAP1LC3BPLK4SIRT1SIRT2SIRT3
SCHEMBL5362880 0.80 PLK4 (0.57) MAP3K7TAB1MAP1LC3BPLK4SIRT1
SCHEMBL7132034 0.80 LRRK2 (0.50) MAP1LC3BPLK4SIRT1SIRT2SIRT3
SCHEMBL5361530 0.79 LRRK2 (0.49) PLK4ALDH1A1MAPTLRRK2RET
SCHEMBL5358356 0.79 AR (0.52) LRRK2MDM2
SCHEMBL7138980 0.79 KMT2A (0.48) MAP1LC3BPLK4SIRT1SIRT2SIRT3
SCHEMBL7134446 0.79 NPC1 (0.43) MAP3K7TAB1MAP1LC3BPLK4SIRT1
SCHEMBL5367274 0.78 MEN1 (0.53) PLK4KMT2ARAF1LRRK2PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MAP3K7 184/4885TAB1 756/4885MAP1LC3B 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.